4.7 Article

Capsaicin treatment reduces nasal hyperreactivity and transient receptor potential cation channel subfamily V, receptor 1 (TRPV1) overexpression in patients with idiopathic rhinitis

期刊

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 133, 期 5, 页码 1332-U544

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2013.08.026

关键词

Capsaicin treatment; idiopathic rhinitis; nasal hyperreactivity; TRPV1; afferent nerves; TRPV1-SP signaling pathway

资金

  1. Science and Technology in Flanders, Belgium (IWT)
  2. fellowship from the Fund for Scientific Research Flanders, Belgium (FWO)
  3. postdoctoral researcher of the Fund for Scientific Research (FWO)
  4. governmental grant (Odysseus program) [G. 0905.07]
  5. Belgian Federal Government [IUAP P6/28, G. 0565.07, G. 0686.09]
  6. IWT (TBM project) [130260]
  7. Research Council of the KU Leuven (GOA) [14/011, EF/95/010, PFV/10/006]

向作者/读者索取更多资源

Background: Idiopathic rhinitis (IR) is a prevalent condition for which capsaicin nasal spray is the most effective treatment. However, the mechanisms underlying IR and the therapeutic action of capsaicin remain unknown. Objective: We sought to investigate the molecular and cellular bases of IR and the therapeutic action of capsaicin. Methods: Fourteen patients with IR and 12 healthy control subjects (HCs) were treated with intranasal capsaicin. The therapeutic effect was assessed in patients with IR by using visual analog scale and therapeutic response evaluation scores, and nasal hyperreactivity was evaluated by means of cold dry air provocation. Nasal samples served to measure the levels of neuromediators and expression of chemosensory cation channels, protein gene product 9.5 (PGP 9.5), and the mast cell marker c-kit. The effects of capsaicin were also tested in vitro on human nasal epithelial cells and mast cells. Results: Patients with IR had higher baseline transient receptor potential cation channel subfamily V, receptor 1 (TRPV1) expression in the nasal mucosa and higher concentrations of substance P (SP) in nasal secretions than HCs. Symptomatic relief was observed in 11 of 14 patients with IR after capsaicin treatment. Expression of TRPV1; transient receptor potential cation channel subfamily M, receptor 8 (TRPM8); and PGP 9.5 was only reduced in patients with IR after capsaicin treatment. Capsaicin did not alter c-KIT expression or nasal epithelial morphology in patients with IR and HCs nor did it induce apoptosis or necrosis in cultured human nasal epithelial cells and mast cells. Conclusion: IR features an overexpression of TRPV1 in the nasal mucosa and increased SP levels in nasal secretions. Capsaicin exerts its therapeutic action by ablating the TRPV1-SP nociceptive signaling pathway in the nasal mucosa.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Otorhinolaryngology

Fluticasone propionate suppresses the SARS-CoV-2 induced increase in respiratory epithelial permeability in vitro

Katleen Martens, Emiel Vanhulle, An-Sofie Viskens, Brecht Steelant, Peter W. Hellings, Kurt Vermeire

Summary: This study found that fluticasone propionate has preventive potential in SARS-CoV-2 infection, as it can prevent virus-induced epithelial barrier disruption and infection, as well as reduce ACE2 expression.

RHINOLOGY (2023)

Letter Otorhinolaryngology

The EUFOREA pocket guide for chronic rhinosinusitis

P. W. Hellings, W. J. Fokkens, R. Orlandi, G. F. Adriaensen, I. Alobid, F. M. Baroody, L. Bjermer, B. A. Senior, A. Cervin, N. A. Cohen, J. Constantinidis, E. De Corso, M. Desrosiers, Z. Diamant, R. G. Douglas, S. Gane, P. Gevaert, J. K. Han, R. J. Harvey, C. Hopkins, R. C. Kern, B. N. Landis, J. T. Lee, S. E. Lee, A. Leunig, V. J. Lund, M. Bernal-Sprekelsen, J. Mullol, C. Philpott, E. Prokopakis, S. Reitsma, D. Ryan, S. Salmi, G. Scadding, R. J. Schlosser, A. Steinsvik, P. V. Tomazic, E. Van Staeyen, T. Van Zele, O. Vanderveken, A-S Viskens, D. Conti, M. Wagenmann

RHINOLOGY (2023)

Review Otorhinolaryngology

Management paradigms for chronic rhinosinusitis in individuals with asthma: An evidence-based review with recommendations

Amarbir S. S. Gill, Jeremiah A. A. Alt, Kara Y. Y. Detwiller, Nicholas R. R. Rowan, Stacey T. T. Gray, Peter W. W. Hellings, Shyam R. R. Joshi, Jivianne T. T. Lee, Zach M. M. Soler, Bruce K. K. Tan, Jennifer L. L. Taylor-Cousar, Sarah K. K. Wise, Tara J. J. Wu, Daniel M. M. Beswick

Summary: This systematic review examined the management strategies for chronic rhinosinusitis with asthma (CRSwA). The results showed that medication, endoscopic sinus surgery, and biologic medications can improve quality of life and asthma control in CRSwA patients. It is recommended to treat CRSwA in a stepwise manner, starting with non-biologic medications and escalating to second-line treatments, while also managing asthma concurrently.

INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY (2023)

Article Otorhinolaryngology

EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023*

W. J. Fokkens, An-Sofie Viskens, Vibeke Backer, Diego Conti, Eugenio de Corso, Philippe Gevaert, Glenis K. Scadding, Martin Wagemann, Manuel Bernal Sprekelsen, Adam Chaker, Enrico Heffler, Joseph K. Han, Elizabeth Van Staeyen, Claire Hopkins, Joaquim Mullol, Anju Peters, Sietze Reitsma, Brent A. Senior, Peter W. Hellings

Summary: Severe chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating disease with significant impact on quality of life, often characterized by type 2 inflammatory reaction and comorbidities like asthma, allergies, and NSAID-Exacerbated Respiratory Disease. The European Forum for Research and Education in Allergy and Airway diseases presents practical guidelines for patients undergoing biologic treatment, including updated criteria for patient selection and recommendations for monitoring drug effects and making treatment decisions. Gaps in current knowledge and unmet needs in the field are also discussed.

RHINOLOGY (2023)

Article Otorhinolaryngology

Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up

Martin Desrosiers, Zuzana Diamant, Paolo W. Castelnuovo, Peter W. K. Hellings, Joseph K. T. Han, Anju T. Peters, Jared G. Silver, Steven G. Smith, Abigail R. Fuller, Ana R. H. Sousa, Robert H. Chan, Philippe Gevaert, SYNAPSE Study Investigators

Summary: In the SYNAPSE study, mepolizumab given every 4 weeks showed sustained clinical benefits in patients with severe CRSwNP even after discontinuation, including reduction in nasal polyp size, improvement in symptoms and quality of life, and reduction in corticosteroid use and sinus surgeries.

INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY (2023)

Review Allergy

The Management of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With Biologics

A. Wautlet, C. Bachert, M. Desrosiers, Peter W. Hellings, Anju T. Peters

Summary: Chronic rhinosinusitis with nasal polyps is a prevalent condition that has significant implications for both patients and society. The development of biologic medications has proven to be effective in treating this condition, leading to improvements in patient outcomes and quality of life. This review examines the treatment options and explores the available evidence regarding patient selection, monitoring after treatment initiation, and comparisons with other treatment options such as sinus surgery.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2023)

Article Allergy

Health-Related Quality of Life Impairment Among Patients with Severe Chronic Rhinosinusitis with Nasal Polyps in the SINUS-24 Trial

Jorge F. Maspero, Asif H. Khan, Carl Philpott, Peter W. Hellings, Claire Hopkins, Martin Wagenmann, Shahid Siddiqui, Jerome Msihid, Scott Nash, Chien-Chia Chuang, Siddhesh Kamat, Paul J. Rowe, Yamo Deniz, Juby A. Jacob-Nara

Summary: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease with severe symptoms. This study compared the physical and mental health-related quality of life (HRQoL) and overall health status of severe CRSwNP patients with the general population and other chronic diseases. The results showed that the HRQoL of CRSwNP patients was lower than the general population and similar to diseases such as diabetes and asthma.

JOURNAL OF ASTHMA AND ALLERGY (2023)

Review Environmental Sciences

Impact of environmental nitrogen pollution on pollen allergy: A scoping review

Paulien Verscheure, Olivier Honnay, Niko Speybroeck, Robin Daelemans, Nicolas Bruffaerts, Brecht Devleesschauwer, Tobias Ceulemans, Laura Van Gerven, Raf Aerts, Rik Schrijvers

Summary: The increase in allergies to aeroallergens is attributed to interactions with environmental and lifestyle changes, with environmental nitrogen pollution potentially being a key driver. While the ecological impact of nitrogen pollution is well understood, its indirect effect on allergies in humans is not well documented. This literature review focuses on the impact of nitrogen pollution on plant communities, plant productivity, and pollen properties, and how these changes contribute to allergy burden. The majority of studies have examined the impact of atmospheric nitrogen pollution on pollen and allergens, leading to allergy symptoms, but limited research has been conducted on the impact of soil and aqueous nitrogen pollution on pollen allergenic reactivity.

SCIENCE OF THE TOTAL ENVIRONMENT (2023)

Article Medicine, Research & Experimental

Leukocyte- and platelet-rich fibrin in endoscopic endonasal skull base reconstruction: study protocol for a multicenter prospective, parallel-group, single-blinded randomized controlled non-inferiority trial

Birgit Coucke, Anais Van Hoylandt, Mark Jorissen, Jeroen Meulemans, Thomas Decramer, Johannes van Loon, Vincent Vander Poorten, Tom Theys, Laura Van Gerven

Summary: This study aims to investigate the use of autologous leukocyte- and platelet-rich fibrin (L-PRF) membranes as an alternative to commercially available fibrin sealants in endoscopic endonasal transsphenoidal approaches (EETA) for skull base reconstruction. The trial will be conducted in three different centers in Belgium, with patients randomized into L-PRF group and commercially available fibrin sealants group. The primary endpoint is postoperative cerebrospinal fluid leakage, and secondary endpoints include identification of risk factors for reconstruction failure, assessment of rhinological symptoms, and interference with postoperative imaging.

TRIALS (2023)

Letter Allergy

A EUFOREA comment on a lost comorbidity of asthma

Diego M. Conti, Peter W. Hellings, Zuzana Diamant, Leif Bjermer, Milos Jesenak, Vibeke Backer, Wytske Fokkens, Susanne Lau, Elizabeth Van Staeyen, Glenis K. Scadding

Summary: This paper examines the epidemiology of comorbidities in asthmatic patients, focusing on the relevance of chronic rhinosinusitis (CRS) with or without nasal polyps (CRSwNP or CRSsNP) as an important comorbidity that is often overlooked. The authors argue that CRS should have been included in the analysis due to its high incidence, its association with asthma, and the impact it has on asthma control and severity. They suggest that targeted therapies used for severe asthma may also be effective for the treatment of nasal polyps.

ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY (2023)

Meeting Abstract Allergy

Change in nasal polyp size as an indicator of treatment response: SYNAPSE trial analysis

Amber Luong, Joshua Levy, Ludger Klimek, Richard Harvey, Jared Silver, Steven Smith, Abby Fuller, Robert Chan, Peter Hellings

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2023)

Review Allergy

Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)?

Dorien Van Broeck, Brecht Steelant, Glenis Scadding, Peter W. Hellings

Summary: Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) is a clinical syndrome characterized by nasal polyposis, asthma, and intolerance to aspirin/NSAID. It affects approximately 15% cases of severe asthma, 10% of nasal polyps and 9% of rhinosinusitis. N-ERD results in associated asthma exacerbations, oral corticosteroids bursts, corticosteroid-dependent disease, and multiple endoscopic sinus surgeries. Unknown influences cause polyp epithelium to release alarmins, activating lymphoid cells and causing complex type 2 inflammation. Treatment strategies for N-ERD include drug therapies, aspirin desensitization, monoclonal antibodies, and other therapies associated.

FRONTIERS IN ALLERGY (2023)

Article Allergy

Determinants of uncontrolled allergic rhinitis in Kinshasa hospitals

Patricia K. Kakobo, Hilaire K. Kalala, Joseph K. Kelekele, Paulin B. Mutombo, Dieudonne T. Nyembue, Peter W. Hellings, Jean-Marie N. Kayembe

Summary: This study aims to identify the determinants of uncontrolled allergic rhinitis (UCAR) in a hospital setting in Kinshasa, Democratic Republic of Congo. The study found that factors associated with UCAR include age below 30 years, low vitamin D level, and persistent as well as moderate to severe allergic rhinitis.

FRONTIERS IN ALLERGY (2023)

Article Microbiology

Stability of magistral phage preparations before therapeutic application in patients with chronic rhinosinusitis, sepsis, pulmonary, and musculoskeletal infections

Saartje Uyttebroek, Laura Bessems, Willem-Jan Metsemakers, Yves Debaveye, Laura Van Gerven, Lieven Dupont, Melissa Depypere, Jeroen Wagemans, Rob Lavigne, Maya Merabishvili, Jean-Paul Pirnay, David Devolder, Isabel Spriet, Jolien Onsea

Summary: This study investigated the stability of bacteriophage preparations used in the treatment of various infections. The results showed that the titer of bacteriophages decreased after storage, indicating the importance of maintaining therapeutic concentrations. The study also found that storing bacteriophage solutions in polypropylene syringes helped maintain stability. Nasal irrigation or infusion through a catheter did not affect the titer of bacteriophages.

MICROBIOLOGY SPECTRUM (2023)

Meeting Abstract Gastroenterology & Hepatology

Role of airborne and food antigen cross-reactivity in the association between allergic airway pathology and irritable bowel syndrome

M. Cuende-Estevez, S. Cuypers, W. Backaert, H. Hussein, I. Appeltans, K. Bellens, J. Vanoirbeek, L. Van Gerven, J. Aguilera-Lizarraga, G. Boeckxstaens

NEUROGASTROENTEROLOGY AND MOTILITY (2023)

暂无数据